STUDIES ON OLIGONUCLEOTIDES CONTAINING POSITIVELY CHARGED BASES

含正电荷碱基寡核苷酸的研究

基本信息

  • 批准号:
    6204070
  • 负责人:
  • 金额:
    $ 13.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-01 至 2000-08-31
  • 项目状态:
    已结题

项目摘要

The overall aim of this project is to determine the stability of triplex DNAs formed between antigene oligodeoxynucleotides containing positively charged bases and duplex DNA targets. The ability of the charged bases, within the triplex, to interact with the different Watson-Crick base pair combinations will also be determined. Antigene oligodeoxynucleotides containing thymidine (T), cytidine (C), and other modified deoxynucleosides including ones possessing positively charged bases such as 3-methyldeoxycytidine (MdC+) will be synthesized. Target duplex DNA will also be synthesized such that one strand of the DNA will be purine- rich containing one or only a few pyrimidine interruptions and the other will be pyrimidine-rich. The stabilities of these triplexes will be primarily determined by ultraviolet (uv) melting studies. The antigene oligonucleotides and duplex DNA targets will be synthesized using standard phosphoramidite [1] chemistry and a DNA synthesizer. This study will also include the synthesis and investigation of the intramolecular stacking interaction occurring in dinucleoside monophosphates and trinucleoside diphosphates incorporated with the positively charged nucleoside, 3- methylcytidine. Finally, the zwitterionic 5'-5' dinucleoside monophosphate will be tested as a potential vehicle for the introduction of antiviral dideoxynucleosides as the 5'-nucleotide.
这个项目的总体目标是确定三联体的稳定性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NORMAN S KONDO其他文献

NORMAN S KONDO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NORMAN S KONDO', 18)}}的其他基金

UDC & LCC PARTNERS IN CANCER RES TRAIN ED & OUTREACH
UDC
  • 批准号:
    6515108
  • 财政年份:
    2001
  • 资助金额:
    $ 13.19万
  • 项目类别:
UDC & LCC PARTNERS IN CANCER RES TRAIN ED & OUTREACH
UDC
  • 批准号:
    6634056
  • 财政年份:
    2001
  • 资助金额:
    $ 13.19万
  • 项目类别:
UDC & LCC PARTNERS IN CANCER RES TRAIN ED & OUTREACH
UDC
  • 批准号:
    6335858
  • 财政年份:
    2001
  • 资助金额:
    $ 13.19万
  • 项目类别:
STUDIES ON OLIGONUCLEOTIDES CONTAINING POSITIVELY CHARGED BASES
含正电荷碱基寡核苷酸的研究
  • 批准号:
    6107003
  • 财政年份:
    1998
  • 资助金额:
    $ 13.19万
  • 项目类别:
STUDIES ON OLIGONUCLEOTIDES CONTAINING POSITIVELY CHARGED BASES
含正电荷碱基寡核苷酸的研究
  • 批准号:
    6239889
  • 财政年份:
    1997
  • 资助金额:
    $ 13.19万
  • 项目类别:
CROSS-LINKED ANTIGENE OLIGOMERS EFFECT ON TRANSCRIPTION
交联抗原寡聚物对转录的影响
  • 批准号:
    6179222
  • 财政年份:
    1996
  • 资助金额:
    $ 13.19万
  • 项目类别:
CROSS-LINKED ANTIGENE OLIGOMERS EFFECT ON TRANSCRIPTION
交联抗原寡聚物对转录的影响
  • 批准号:
    2734311
  • 财政年份:
    1996
  • 资助金额:
    $ 13.19万
  • 项目类别:
CROSS-LINKED ANTIGENE OLIGOMERS EFFECT ON TRANSCRIPTION
交联抗原寡聚物对转录的影响
  • 批准号:
    6018250
  • 财政年份:
    1996
  • 资助金额:
    $ 13.19万
  • 项目类别:
CROSS-LINKED ANTIGENE OLIGOMERS EFFECT ON TRANSCRIPTION
交联抗原寡聚物对转录的影响
  • 批准号:
    2166031
  • 财政年份:
    1996
  • 资助金额:
    $ 13.19万
  • 项目类别:
CROSS-LINKED ANTIGENE OLIGOMERS EFFECT ON TRANSCRIPTION
交联抗原寡聚物对转录的影响
  • 批准号:
    2444413
  • 财政年份:
    1996
  • 资助金额:
    $ 13.19万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 13.19万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 13.19万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 13.19万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 13.19万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 13.19万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 13.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 13.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了